title: Cell fusion between dendritic cells and whole tumor cells.
abstract: We have developed cell fusion vaccines generated with dendritic cells (DCs) and whole tumor cells to induce antigen-specific antitumor immunity. This approach allows DCs to be exposed to the entire repertoire of tumor-associated antigens (TAAs) originally expressed by the tumor cell, to process them endogenously, and to present antigenic epitopes thought the MHC class I and class II pathways to activate both CD8+ and CD4+ T cells, respectively. The therapeutic efficacy of DC/tumor fusion cell vaccines requires the improved immunogenicity of both cells. Here, we describe the strategy to generate DC/tumor fusion cells.
authors.affiliation: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Jikei University School of Medicine, 163-1 Kashiwa-shita, Kashiwa, Chiba, 277-8564, Japan, shigeo_koido@jikei.ac.jp.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Koido
authors.forename: Jianlin
authors.initials: J
authors.lastname: Gong
mesh_terms: D000951:Antigens, Neoplasm / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D002459:Cell Fusion / Q000379:methods; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D006801:Humans; D006822:Hybrid Cells / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D019496:Cancer Vaccines